Biogen (BIIB34) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB −2,69%	1 068,24	−29,57	−2,69%	—	1 097,81	1 087,76	1 087,76	1 067,42	—	—
SIXC Communications SIXC Communications	SIXC −0,89%	606,59	−5,44	−0,89%	—	612,03	612,03	612,03	606,13	—	—
SIXE Energy SIXE Energy	SIXE +2,19%	1 247,21	+26,78	+2,19%	—	1 220,43	1 221,99	1 247,60	1 221,99	—	—
SIXI Industrials SIXI Industrials	SIXI −1,82%	1 727,58	−31,94	−1,82%	—	1 759,52	1 754,31	1 754,31	1 723,60	—	—
SIXM Financials SIXM Financials	SIXM −0,32%	629,54	−2,00	−0,32%	—	631,54	631,27	633,99	628,63	—	—
SIXR Staples SIXR Staples	SIXR −0,42%	853,60	−3,56	−0,42%	—	857,16	858,91	861,71	852,33	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −1,56%	212,04	−3,37	−1,56%	—	215,41	215,41	215,41	211,88	—	—
SIXT Technology SIXT Technology	SIXT −1,78%	3 549,76	−64,39	−1,78%	—	3 614,15	3 556,24	3 598,36	3 516,86	—	—
SIXU Utilities SIXU Utilities	SIXU −2,40%	886,49	−21,81	−2,40%	—	908,30	906,55	906,55	885,88	—	—
SIXV Health care SIXV Health care	SIXV −1,08%	1 464,34	−16,06	−1,08%	—	1 480,40	1 479,55	1 484,43	1 462,52	—	—
SIXY Discretionary SIXY Discretionary	SIXY −1,84%	2 354,25	−44,12	−1,84%	—	2 398,37	2 373,09	2 373,09	2 350,27	—	—

BIIB34:BVMF

Biogen

162,24 BRL

+2,07%

(+3,29) 1 D

15. mai, 16:56:00 GMT-3 · BRL

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for BIIB34 …

Åpne

162,24 BRL

Høy

162,24 BRL

Lav

162,24 BRL

Markedsverdi

28,49 mrd.

Snittvolum

23,00

Volum

2,00

52 u høy

172,26 BRL

52 u lav

113,64 BRL

Utestående aksjer

147,64 mill.

Antall ansatte

Relaterte aksjer

Alnylam Pharmaceuticals Inc Bdr

Nyhetssaker

Fra kilder på nettet

Seeking Alpha

for 1 døgn siden

Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity (BIIB)

Investing.com

for 2 døgn siden

Guggenheim reiterates Biogen stock rating on Alzheimer’s drug data

TradingView

for 2 døgn siden

Key facts: Biogen SYFOVRE CVR $4; Apellis buyout done; shares dip

GuruFocus

for 2 døgn siden

Biogen Shares Jump 10% After Advancing Alzheimer's Tau Drug

Profil

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia

Om Biogen

Administrerende direktørChristopher A. Viehbacher

Ansatte7,5k

Grunnlagt1978

HovedkontorCambridge, Massachusetts, USA

Sektor-

Nettstedbiogen.com

Alle verdier i USD	juni 2025	sep. 2025	des. 2025	mars 2026
Inntekt	2,65 mrd.	2,53 mrd.	2,28 mrd.	2,48 mrd.
Varekostnad	946,20 mill.	508,60 mill.	443,40 mill.	610,20 mill.
Direkte driftskostnader	946,20 mill.	508,60 mill.	443,40 mill.	610,20 mill.
Utgifter til forskning og utvikling	-	431,80 mill.	501,00 mill.	482,20 mill.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	581,30 mill.	592,80 mill.	685,20 mill.	607,30 mill.
Driftskostnader	783,70 mill.	1,25 mrd.	1,39 mrd.	1,30 mrd.
Totale driftskostnader	1,73 mrd.	1,76 mrd.	1,83 mrd.	1,91 mrd.
Driftsinntekter	915,60 mill.	778,60 mill.	447,70 mill.	567,40 mill.
Andre ikke-operasjonelle inntekter	−3,30 mill.	15,80 mill.	17,40 mill.	−1,10 mill.
EBT inkludert uvanlige elementer	744,00 mill.	557,30 mill.	−56,00 mill.	377,70 mill.
EBT uten uvanlige elementer	861,60 mill.	748,30 mill.	423,10 mill.	530,10 mill.
Kostnad for inntektsskatt	109,20 mill.	90,80 mill.	−7,10 mill.	58,20 mill.
Faktisk avgiftssats	14,68 %	16,29 %	12,68 %	15,41 %
Andre driftskostnader	75,00 mill.	87,20 mill.	69,90 mill.	74,20 mill.
Nettoinntekt	634,80 mill.	466,50 mill.	−48,90 mill.	319,50 mill.
Netto fortjenestemargin	24,00 %	18,40 %	−2,15 %	12,89 %
Resultat per aksje	5,47	4,81	1,99	3,57
Rente- og investeringsinntekter	32,30 mill.	31,60 mill.	37,20 mill.	37,90 mill.
Rentekostnader	−72,60 mill.	−67,40 mill.	−67,50 mill.	−67,60 mill.
Netto rentekostnader	−40,30 mill.	−35,80 mill.	−30,30 mill.	−29,70 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	1,11 mrd.	980,80 mill.	647,90 mill.	771,80 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning